Loading...
Loading...
NEW YORK, NY · CIK 0001263508
New positions
10
Added to
21
Trimmed
4
Exited
8
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $9.36B across 97 positions in their Q4 2024 SEC 13F filing (period ending 2024-12-31). The top 10 positions account for 76.5% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | INCYIncyte Corporation | $2.12B | 22.68% | +0.0% |
| 2 | ONCBeiGene, Ltd. | $1.76B | 18.81% | -9.8% |
| 3 | ACADACADIA Pharmaceuticals Inc. | $786.81M | 8.40% | - |
| 4 | MDGLMadrigal Pharmaceuticals, Inc. | $609.30M | 6.51% | - |
| 5 | SMMTSummit Therapeutics Inc. | $435.86M | 4.66% | - |
| 6 | RVMDRevolution Medicines, Inc. | $347.16M | 3.71% | +4.9% |
| 7 | INSMInsmed Incorporated | $345.67M | 3.69% | +13.4% |
| 8 | RYTMRhythm Pharmaceuticals, Inc. | $340.60M | 3.64% | -4.9% |
| 9 | KYMRKymera Therapeutics, Inc. | $241.22M | 2.58% | - |
| 10 | KODKodiak Sciences Inc. | $172.24M | 1.84% | - |
| Stock | Value | Shares |
|---|---|---|
| IONS 1.75 06/15/28Ionis Pharmaceuticals, Inc. | $29.54M | 30,000,000 |
| GRALGRAIL, Inc. | $29.10M | 1,630,125 |
| CADLCandel Therapeutics, Inc. | $25.88M | 2,981,983 |
| VIRVir Biotechnology, Inc. | $7.96M | 1,084,539 |
| NTLAIntellia Therapeutics, Inc. | $7.51M | 644,116 |
| BNTXBioNTech SE | $5.13M | 45,031 |
| IRONDisc Medicine, Inc. | $4.88M | 77,050 |
| DBVTDBV Technologies S.A. | $4.52M | 1,461,425 |
| RCKTRocket Pharmaceuticals, Inc. | $1.22M | 97,079 |
| PTCTPTC Therapeutics, Inc. | $920.86K | 20,400 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.